Nicox Shares Surge 12% in Stock Market Following Debt Repayment
Nicox shares closed up 12% on Monday, January 5, following the full repayment of secured debt to Kreos Capital, boosting investor confidence and financial flexibility.
Significant Stock Performance and Debt Repayment
Nicox shares ended this Monday, January 5, with a 12% increase at 0.35 euros, up from 0.31 euros the previous day, on a high trading volume representing 2.47% of the capital. This performance indicates an acceleration of the ongoing momentum, with the stock posting a 16.67% increase over the week and a 12.54% gain over the year. The ophthalmology company announced this morning the full repayment of its secured debt to Kreos Capital using its available cash by the end of 2025, resulting in the lifting of all securities on its assets. This move also terminates Kreos Capital's right to appoint an auditor to the board. As of December 31, 2025, Nicox's residual debt amounted to 0.3 million euros, related to the balance of a COVID loan, which will be repaid by the end of August 2026.
New Financing through Bond Issue
In conjunction with this repayment, Nicox has secured new financing through a bond issue subscribed by a group of European investors, including Vester Finance, consisting of 3 million euros in convertible bonds and 1 million euros in simple bonds. The convertible bonds, with a nominal value of 10 euros each, were subscribed at 92% of their nominal value, amounting to a total price of approximately 3 million euros paid in full at the time of subscription. This financing, which is unsecured and without associated guarantees, allows the company to enhance its financial flexibility. Based on expected milestone payments, including the submission of the market approval application for NCX 470 in the United States and a standard 12-month review period, the company estimates that its operations are funded beyond the end of 2027.
Technical Outlook and Future Catalysts
Technically, Nicox is now trading above its previous resistance level at 0.31 euros, which also corresponds to its 50-day moving average. The RSI stands at 65, indicating renewed interest without overt excess, while the stock price is above its 20, 50, and 200-day moving averages, positioned at 0.30 euros, 0.31 euros, and 0.30 euros, respectively. The stock is also on the upper boundary of its Bollinger Bands set at 0.31 euros, signaling a short-term increase in volatility. This setup suggests a bullish trend reinforced by the day's financial announcement. The next expected catalyst is the filing for market approval for NCX 470 in the United States, scheduled for summer 2026, following a pre-NDA meeting planned for the first quarter.
